Syenza News — health technology assessment, market access and health economics

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion
The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Recent Posts

Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
Nov 17
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
Nov 17
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows
Nov 17
Learning Health System Frameworks and AI in US Care: A Scoping Review
Nov 16
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
Nov 16Syenza's Top Picks

Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit
Nov 6, 2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
Nov 10, 2026
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Nov 10, 2026
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November
Nov 10, 2026
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
Nov 9, 2026
Medicare drug price negotiation: CMS sets permanent rules
Nov 9, 2026Latest News

Cardiovascular And Metabolic Diseases
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA’s CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.

Cardiovascular And Metabolic Diseases
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca’s Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess

Healthcare Spending Free account
NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending
The NHLS governance crisis reached Parliament with R1.8 billion in irregular spending, an interim board and a disputed IP Capital consultancy.

Clinical Guidelines And Protocols
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess

Clinical Guidelines And Protocols
ACS Updates Prostate Cancer Screening Guideline for PSA Testing
“The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69.” #SyenzaNews #ProstateCancer

Health Policy
SADC Pharmaceutical Pooled Procurement Charter Signed in Durban
The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess

Clinical Practice
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess

Drug Pricing
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.

Cost Effectiveness Analysis
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Artificial Intelligence And Machine Learning
Artificial Intelligence in Medicine Regulation: From Concept to Practice
EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.



